The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab enhances survival rates in both primary and metastatic HER2-positive breast cancer patients [20, 21].”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,475
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0245 · Cited by 1,171 · cited 1×
“Although a large number of chemotherapy regimens have been tested in randomized studies, there is no internationally accepted standard of care, and uncertainty remains regarding the choice of the chemotherapy regimen [7].”
BackgroundAkiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Gastric cancer epidemiology and risk factors
Kelley, J. R., & Duggan, J. M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00534-6 · Cited by 750
Tanner, M., Hollmén, M., Junttila, T. T., Kapanen, A. I., Tommola, S., Soini, Y., Helin, H., Salo, J., Joensuu, H., Sihvo, E., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi064 · Cited by 665
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Mutations of the human E-cadherin (CDH1) gene
Berx, G., Becker, K.-F., Höfler, H., & van Roy, F. (1998) · Human Mutation · doi:10.1002/(sici)1098-1004(1998)12:4<226::aid-humu2>3.0.co;2-d · Cited by 607
(1996) · PubMed · Cited by 554
Nakajima, M., Sawada, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., Sakaguchi, T., Hirao, T., & Nakano, H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9%3c1894::aid-cncr3%3e3.0.co;2-j · Cited by 494
Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M., & Sasaki, T. (1991) · PubMed · Cited by 375
Cuello, M. A., Ettenberg, S. A., Clark, A. S., Keane, M., Posner, R. H., Nau, M. M., Dennis, P. A., & Lipkowitz, S. (2001) · PubMed · Cited by 370
HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
Park, D. I., Yun, J. W., Park, J. H., Oh, S. J., Kim, H. J., Cho, Y. K., Sohn, C. I., Jeon, W. K., Kim, B. I., Yoo, C. H., et al. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-9057-1 · Cited by 329
Montgomery, E., Goldblum, J. R., Greenson, J. K., Haber, M. M., Lamps, L. W., Lauwers, G. Y., Lazenby, A. J., Lewin, D. N., Robert, M. E., Washington, K., et al. (2001) · Human Pathology · doi:10.1053/hupa.2001.23511 · Cited by 291
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
Kaptain, S., Tan, L. K., & Chen, B. (2001) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200109000-00001 · Cited by 208
Takehana, T., Kunitomo, K., Kono, K., Kitahara, F., Iizuka, H., Matsumoto, Y., Fujino, M. A., & Ooi, A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10257 · Cited by 195
Fujimoto-Ouchi, K., Sekiguchi, F., Yasuno, H., Moriya, Y., Mori, K., & Tanaka, Y. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0337-z · Cited by 193
Helicobacter pylori and gastric cancer: state of the art.
Corréa, P. (1996) · PubMed · Cited by 186
Garc�a, I., Vizoso, F., Mart�n, A., Sanz, L., Abdel-Lah, O., Raigoso, P., & Garc�a-Mu�iz, J. L. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.05.010 · Cited by 177
Tokunaga, A., Onda, M., Okuda, T., Teramoto, T., Fujita, I., Mizutani, T., Kiyama, T., Yoshiyuki, T., Nishi, K., & Matsukura, N. (1995) · Cancer · doi:10.1002/1097-0142(19950315)75:6+<1418::aid-cncr2820751505>3.0.co;2-y · Cited by 150
HER 2/neu protein expression in colorectal cancer
Schuell, B., Gruenberger, T., Scheithauer, W., Zielinski, C. C., & Wrba, F. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-123 · Cited by 147
Hollywood, D. P., & Hurst, H. C. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05891.x · Cited by 136
ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix.
Mitra, A., Murty, V. V. V. S., Pratap, M., Sodhani, P., & Chaganti, R. S. K. (1994) · PubMed · Cited by 122
Chemotherapy for gastric cancer
Sastre, J., García-Sáenz, J. Á., & Díaz‐Rubio, E. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i2.204 · Cited by 119
HER-2/neu Oncogene Characterization in Head and Neck Squamous Cell Carcinoma
Beckhardt, R. N., Kiyokawa, N., Li, X., Liu, T.-J., Hung, M., El‐Naggar, A. K., Zhang, H.-Z., & Clayman, G. L. (1995) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1995.01890110041008 · Cited by 91
Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells
Sasano, H., Date, F., Imatani, A., Asaki, S., & Nagura, H. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90236-a · Cited by 83
Oh, S. Y., Kwon, H.-C., Kim, S.-H., Jang, J. S., Kim, M. C., Kim, K. H., Han, J., Kim, C. O., Kim, S., Jeong, J., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-123 · Cited by 74
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches
Scartozzi, M., Galizia, G., Freddari, F., Berardi, R., Cellerino, R., & Cascinu, S. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.01.001 · Cited by 71
Cox-2 and Her2/neu co-expression in invasive bladder cancer
Eltze, E., Wülfing, C., von Struensee, D., Piechota, H., Buerger, H., & Hertle, L. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.6.1525 · Cited by 58
Cited by
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K., & Prenen, H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30354-3 · Cited by 1,793
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Fanta, P., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0008 · Cited by 1,684
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Metadata
- Authors
- Gravalos, C., & Jimeno, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 19
- Issue
- 9
- Pages
- 1523-1529
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2169560977
- Cited by
- 1,184
- References
- 34
- FWCI
- 30.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.